← Leaderboards
Richard J O'Reilly
Sloan-Kettering Institute For Cancer Res
$17,498,839
Attributed
$17,498,839
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.7M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$75,853,413 · 21
By mechanism
P01$73,175,407 · 18
U01$1,527,321 · 1
R21$755,231 · 1
U54$395,454 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsT-LymphocyteLeukemiaAllogenicPeptidesAllelesIn VitroAllograftingIn VivoEpitopesTumorRelapseProgramsTransplantationMarrowCellsInfectionAdoptive TransferReconstitutionHematopoieticAntigensResponseCytomegalovirusClinical Research
Grant awards (99)
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$394,269
P01 · FY2023 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$386,442
P01 · FY2022 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$389,736
P01 · FY2021 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$4,029
P01 · FY2021 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$394,269
P01 · FY2020 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$8,561
P01 · FY2020 · CA · contact PI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells$394,269
P01 · FY2019 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$2,928,248
P01 · FY2017 · CA · contact PI
Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to$400,570
P01 · FY2017 · CA · contact PI
Administrative Core$155,852
P01 · FY2017 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$2,928,248
P01 · FY2016 · CA · contact PI
Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to$433,106
P01 · FY2016 · CA · contact PI
Administrative Core$188,390
P01 · FY2016 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$17,242
P01 · FY2016 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$2,928,248
P01 · FY2015 · CA · contact PI
Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to$433,106
P01 · FY2015 · CA · contact PI
Administrative Core$188,390
P01 · FY2015 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$75,923
P01 · FY2015 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$2,840,400
P01 · FY2014 · CA · contact PI
Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to$420,112
P01 · FY2014 · CA · contact PI
Administrative Core$182,737
P01 · FY2014 · CA · contact PI
Immunobiology for Marrow Allografts for Leukemia$58,683
P01 · FY2014 · CA · contact PI
Immunobioogy for Marrow Allografts for Leukemia$3,166,828
P01 · FY2013 · CA · contact PI
Clinical Trials Evaluating Transplant Strategies and Adoptive Cell Therapies to$433,106
P01 · FY2013 · CA · contact PI
Administrative Core$188,390
P01 · FY2013 · CA · contact PI
A Retrospective and Cross- Sectional Study of Hematopoietic Cell Transplantation$138,681
U54 · FY2013 · AI · contact PI
EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign$379,518
R21 · FY2012 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$150,000
P01 · FY2012 · CA · contact PI
A Retrospective and Cross- Sectional Study of Hematopoietic Cell Transplantation$106,211
U54 · FY2012 · AI · contact PI
The Immunobiology of Marrow Allografts for Leukemia$3,002,066
P01 · FY2011 · CA · contact PI
EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign$375,713
R21 · FY2011 · CA · contact PI
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE$366,186
P01 · FY2011 · CA · contact PI
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &$342,005
P01 · FY2011 · CA · contact PI
A Retrospective and Cross- Sectional Study of Hematopoietic Cell Transplantation$150,562
U54 · FY2011 · AI · contact PI
The Immunobiology of Marrow Allografts for Leukemia$3,117,289
P01 · FY2010 · CA · contact PI
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE$440,614
P01 · FY2010 · CA · contact PI
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &$391,307
P01 · FY2010 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$379,945
P01 · FY2010 · CA · contact PI
The Immunobiology of Marrow Allografts for Leukemia$3,076,095
P01 · FY2009 · CA · contact PI
Molecular Targeting of Developmental Cancers in Children$2,575,193
P01 · FY2009 · CA · contact PI
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE$436,407
P01 · FY2009 · CA · contact PI
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &$385,179
P01 · FY2009 · CA · contact PI
Project 5$377,638
P01 · FY2009 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$375,263
P01 · FY2009 · CA · contact PI
Cellular Immunity Targeting Epithelial Ovarian Cancer$362,183
P01 · FY2009 · CA · contact PI
Core D$134,427
P01 · FY2009 · CA · contact PI
The Immunobiology of Marrow Allografts for Leukemia$2,959,846
P01 · FY2008 · CA · contact PI
Molecular Targeting of Developmental Cancers in Children$2,511,105
P01 · FY2008 · CA · contact PI
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE$428,498
P01 · FY2008 · CA · contact PI
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &$375,823
P01 · FY2008 · CA · contact PI
Project 5$368,313
P01 · FY2008 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$367,027
P01 · FY2008 · CA · contact PI
Cellular Immunity Targeting Epithelial Ovarian Cancer$352,723
P01 · FY2008 · CA · contact PI
Core D$131,376
P01 · FY2008 · CA · contact PI
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$1
U01 · FY2008 · HL · contact PI
Molecular Targeting of Developmental Cancers in Children$2,564,487
P01 · FY2007 · CA · contact PI
The Immunobiology of Marrow Allografts for Leukemia$2,005,952
P01 · FY2007 · CA · contact PI
The Immunobiology of Marrow Allografts for Leukemia$872,075
P01 · FY2007 · CA · contact PI
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE$394,006
P01 · FY2007 · CA · contact PI
Project 5$366,606
P01 · FY2007 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$361,319
P01 · FY2007 · CA · contact PI
Cellular Immunity Targeting Epithelial Ovarian Cancer$350,340
P01 · FY2007 · CA · contact PI
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &$344,620
P01 · FY2007 · CA · contact PI
ADMINISTRATIVE CORE$160,723
P01 · FY2007 · CA · contact PI
Core D$131,045
P01 · FY2007 · CA · contact PI
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$1
U01 · FY2007 · HL · contact PI
The Immunobiology of Marrow Allografts for Leukemia$2,949,927
P01 · FY2006 · CA · contact PI
Molecular Targeting of Developmental Cancers in Children$2,487,338
P01 · FY2006 · CA · contact PI
Project 5$211,778
P01 · FY2006 · CA · contact PI
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth$177,572
P01 · FY2006 · CA · contact PI
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$163,111
U01 · FY2006 · HL · contact PI
Cellular Immunity Targeting Epithelial Ovarian Cancer$160,032
P01 · FY2006 · CA · contact PI
Core D$75,855
P01 · FY2006 · CA · contact PI
The Immunobiology of Marrow Allografts for Leukemia$2,943,616
P01 · FY2005 · CA
Molecular Targeting of Developmental Cancers in Children$2,225,598
P01 · FY2005 · CA
Project 5$206,628
P01 · FY2005 · CA
Cellular Immunity Targeting Epithelial Ovarian Cancer$155,461
P01 · FY2005 · CA
Core D$74,168
P01 · FY2005 · CA
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$2
U01 · FY2005 · HL
The Immunobiology of Marrow Allografts for Leukemia$2,522,446
P01 · FY2004 · CA
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$405,001
U01 · FY2004 · HL
The Immunobiology of Marrow Allografts for Leukemia$358,014
P01 · FY2004 · CA
The Immunobiology of Marrow Allografts for Leukemia$2,294,717
P01 · FY2003 · CA
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$405,001
U01 · FY2003 · HL
The Immunobiology of Marrow Allografts for Leukemia$2,212,710
P01 · FY2002 · CA
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$150,001
U01 · FY2002 · HL
CORE--BIOSTATISTICS CORE$0
P01 · FY2002 · CA
T LYMPHOCYTES FOR TREATMENT OF EBV-RELATED LYMPHOMA$0
P01 · FY2002 · CA
T CELL RECOGNITION OF HOST LEUKEMIA &CONTROL OF CELLS$0
P01 · FY2002 · CA
CLINICAL TRIALS OF ALLOGENIC BMT / STEM CELL TRANSPLANTS$0
P01 · FY2002 · CA
BIOLOGY AND GENETICS OF MARROW ALLOGRAFTS FOR LEUKEMIA$666,929
P01 · FY2001 · CA
IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS$404,203
U01 · FY2001 · HL
T LYMPHOCYTES FOR TREATMENT OF EBV-RELATED LYMPHOMA$0
P01 · FY2001 · CA
SUICIDE GENE MODIFIED EBV ANTIGEN SENSITIZED T CELLS FOR EBV RELATED LYMPHOMA$0
P01 · FY2001 · CA
CLINICAL TRIALS IN MARROW TRANSPLANTATION$0
P01 · FY2001 · CA
BIOLOGY AND GENETICS OF MARROW ALLOGRAFTS FOR LEUKEMIA$2,065,351
P01 · FY2000 · CA
SUICIDE GENE MODIFIED EBV ANTIGEN SENSITIZED T CELLS FOR EBV RELATED LYMPHOMA$245,216
P01 · FY2000 · CA
CLINICAL TRIALS IN MARROW TRANSPLANTATION$245,216
P01 · FY2000 · CA
T LYMPHOCYTES FOR TREATMENT OF EBV-RELATED LYMPHOMA$0
P01 · FY2000 · CA